Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
122.06
+0.01 (0.01%)
Nov 4, 2025, 12:36 PM EST - Market open
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.77B in the quarter ending September 30, 2025, with 2.97% growth. This brings the company's revenue in the last twelve months to $29.09B, up 2.78% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$29.09B
Revenue Growth
+2.78%
P/S Ratio
5.23
Revenue / Employee
$1,652,670
Employees
17,600
Market Cap
151.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
GILD News
- 1 day ago - Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025 - Business Wire
- 3 days ago - Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 - Benzinga
- 4 days ago - Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir) - Business Wire
- 4 days ago - Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Gilead posts higher profit as HIV sales rise, helped by prevention drugs - Reuters
- 4 days ago - Gilead Sciences Announces Third Quarter 2025 Financial Results - Business Wire
- 5 days ago - Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes - Business Wire
- 7 days ago - Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings - CNBC